PGAM
CYTH

Princeton Global Asset Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Princeton Global Asset Management’s Portfolio CYTH Stock Details CYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,466
Closed -$2.73K – 689
2024
Q3 		$2.73K Sell
3,466
-300
-8% -$300 ﹤0.01% 593
2024
Q2 		$4.78K Hold
3,766
– – ﹤0.01% 534
2024
Q1 		$5.24K Buy
3,766
+3,466
+1,155% +$5.73K ﹤0.01% 490
2023
Q4 		$477 Hold
300
– – ﹤0.01% 622
2023
Q3 		$426 Hold
300
– – ﹤0.01% 563
2023
Q2 		$477 Hold
300
– – ﹤0.01% 558
2023
Q1 		$252 Hold
300
– – ﹤0.01% 575
2022
Q4 		$0 Buy
+300
New +$496 ﹤0.01% 592

Other funds holding CYTH

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Princeton Global Asset Management's CYTH Position: Q4 2024 in Review

Princeton Global Asset Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q4 2024, closing a stake of 3,466 shares — an estimated $2.73K sold.

Princeton Global Asset Management first reported a position in CYTH in Q4 2022 and held it in 8 quarters. The position peaked at $5.24K in Q1 2024. 22 funds tracked by Wall St. Rank hold CYTH as of Q4 2024.

  • Princeton Global Asset Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Princeton Global Asset Management sold 3,466 Cyclo Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $2.73K.
  • Princeton Global Asset Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2022 and held it in 8 quarters.
  • Princeton Global Asset Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $5.24K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q4 2024.

Based on Princeton Global Asset Management's 13F filing for Q4 2024, filed 24 Jan 2025.